Qi Li
Dalian Institute of Chemical Physics(CN)Shanghai Jiao Tong University(CN)Chinese Academy of Sciences(CN)First People's Hospital of Yunnan Province(CN)Shanghai Cancer Institute(CN)University of Chinese Academy of Sciences(CN)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Head and Neck Cancer Studies
Most-Cited Works
- → Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial(2022)545 cited
- → Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial(2021)392 cited
- → Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)(2021)341 cited
- → Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study(2017)250 cited
- → Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma(2023)208 cited
- → Dysregulated Glutamate Transporter SLC1A1 Propels Cystine Uptake via Xc− for Glutathione Synthesis in Lung Cancer